Skip to main content
Canadian Medical Association Journal logoLink to Canadian Medical Association Journal
. 1980 Nov 22;123(10):1013–1016.

Labetalol: potent antihypertensive agent that blocks both alpha- and beta-adrenergic receptors.

B J Milne, A G Logan
PMCID: PMC1704976  PMID: 6256045

Abstract

Labetalol was administered as the sole antihypertensive agent to 20 ambulatory patients with mild to moderate hypertension. The mean systolic and diastolic blood pressures (+/- standard error of the mean) with the patients sitting fell significantly (P < 0.001), from 145.5 +/- 3.2 and 103.7 +/- 1.6 mm Hg respectively at the start of labetalol therapy (after a period free of antihypertensive medication) to 125.7 +/- 2.0 and 87.2 +/- 1.1 mm Hg by the end of the trial. The diastolic blood pressure was well controlled (90 mm Hg or less) with labetalol therapy in 90% of the patients. The medication was well tolerated, and no orthostatic fall in the diastolic blood pressure was observed. Pharmacologically labetalol most closely resembles a combination of a nonselective beta-adrenergic blocker like propranolol and a postsynaptic alpha-adrenergic blocker like prazosin.

Full text

PDF
1013

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arbilla S., Langer S. Z. Differences between presynaptic and postsynaptic alpha-adrenoceptors in the isolated nictitating membrane of the cat: effects of metanephrine and tolazoline. Br J Pharmacol. 1978 Oct;64(2):259–264. doi: 10.1111/j.1476-5381.1978.tb17298.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Beilin L. J., Juel-Jensen B. E. Alpha and beta adrenergic blockade in hypertension. Lancet. 1972 May 6;1(7758):979–982. doi: 10.1016/s0140-6736(72)91154-3. [DOI] [PubMed] [Google Scholar]
  3. Blakeley A. G., Summers R. J. The effects of labetalol (AH 5158) on adrenergic transmission in the cat spleen. Br J Pharmacol. 1977 Apr;59(4):643–650. doi: 10.1111/j.1476-5381.1977.tb07733.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Johnson B. F., LaBrooy J., Munro-Faure A. D. Comparative anti-hypertensive effects of labetalol and the combination of oxprenolol and phentolamine. Br J Clin Pharmacol. 1976 Aug;3(4 Suppl 3):783–787. [PubMed] [Google Scholar]
  5. Logan A. G., Milne B. J., Colman J. M. Detection of 'responders' to long-term pindolol therapy from phasic changes in cardiovascular function during acute intravenous administration in essential hypertension. Clin Invest Med. 1978;1(3-4):147–152. [PubMed] [Google Scholar]
  6. Rosengard S. Antihypertensive effect and tolerability of metoprolol during long-term treatment: a multicentre study. J Int Med Res. 1977;5(3):199–206. doi: 10.1177/030006057700500310. [DOI] [PubMed] [Google Scholar]
  7. Volicer L., Liang C. S., Gavras H., Tifft C. P., Kershaw G. R., Gavras I., Griffith D. L., Vukovitch R., Brunner H. R. Effect of nadolol in treatment of hypertension. J Clin Pharmacol. 1979 Feb-Mar;19(2-3):137–147. doi: 10.1002/j.1552-4604.1979.tb02471.x. [DOI] [PubMed] [Google Scholar]

Articles from Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES